

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☒ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	Frazier Life Sciences Public Fund, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a) ☒ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	0.00	
		Shared Voting Power
	6	
	19,445,046.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	19,445,046.00	

9	Aggregate Amount Beneficially Owned by Each Reporting Person
	19,445,046.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	5.6 %
12	Type of Reporting Person (See Instructions)
	PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	FHMLSP, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
	5
	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	6
	19,445,046.00
	Sole Dispositive Power
	7
	0.00
	Shared Dispositive Power
	8
	19,445,046.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person

	19,445,046.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	5.6 %
12	Type of Reporting Person (See Instructions)
	PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	FHMLSP, L.L.C.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	DELAWARE
	Sole Voting Power
5	0.00
	Shared Voting Power
6	19,445,046.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive
8	Power
	19,445,046.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	19,445,046.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	5.6 %
12	Type of Reporting Person (See Instructions)
	OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Frazier Life Sciences X, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)

☒ (b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

5

Sole Voting Power

0.00

Shared Voting Power

6

306,906.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

306,906.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

306,906.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

FHMLS X, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)

☒ (b)

3

Sec Use Only

4 Citizenship or Place of Organization

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

306,906.00

Sole Dispositive Power

7

0.00

Shared Dispositive
Power

8

306,906.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

306,906.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10



Percent of class represented by amount in row (9)

11

0.1 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

FHMLS X, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2



(a)



(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Sole Voting Power

5

0.00

Shared Voting Power

6

306,906.00

Sole Dispositive Power

7

0.00

8 Shared Dispositive
Power

	306,906.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	306,906.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0.1 %
12	Type of Reporting Person (See Instructions)
	OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Frazier Life Sciences XI, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	753,251.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	753,251.00
	Aggregate Amount Beneficially Owned by Each Reporting Person
9	753,251.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0.2 %
12	Type of Reporting Person (See Instructions)
	PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	FHMLS XI, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	DELAWARE
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	753,251.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	Power
	8
	753,251.00
	Aggregate Amount Beneficially Owned by Each Reporting Person
9	753,251.00
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10	☐
	Percent of class represented by amount in row (9)
11	0.2 %
	Type of Reporting Person (See Instructions)
12	PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	FHMLS XI, L.L.C.
2	Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☒ (b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6 753,251.00

Sole Dispositive Power

7 0.00

Shared Dispositive

8 Power

753,251.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 753,251.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10 ☐

Percent of class represented by amount in row (9)

11 0.2 %

Type of Reporting Person (See Instructions)

12 OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1 Frazier Life Sciences XII, L.P.

Check the appropriate box if a member of a Group (see instructions)

2 ☐ (a)
☒ (b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6 1,941,465.00

Sole Dispositive Power

	0.00
	Shared Dispositive
8	Power
	1,941,465.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,941,465.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0.6 %
12	Type of Reporting Person (See Instructions)
	PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	FHMLS XII, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	DELAWARE
	Sole Voting Power
5	0.00
	Shared Voting Power
6	1,941,465.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive
8	Power
	1,941,465.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,941,465.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0.6 %
12	Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	FHMLS XII, L.L.C.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	1,941,465.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	8 Power
	1,941,465.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,941,465.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
	Percent of class represented by amount in row (9)
11	0.6 %
	Type of Reporting Person (See Instructions)
12	OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
---	----------------------------

James N. Topper

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)

☒ (b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

Beneficially
Owned by

6

306,906.00

Each

Sole Dispositive Power

Reporting

7

0.00

Person

With:

Shared Dispositive

8

Power

306,906.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

306,906.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

0.1 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Patrick J. Heron

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)

☒ (b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Number of
Shares

Sole Voting Power

5

Beneficially
Owned by

0.00

Each

6

Shared Voting Power

Reporting Person With:	306,906.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	306,906.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	306,906.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0.1 %
12	Type of Reporting Person (See Instructions)
	IN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 345,154,561 shares of Common Stock outstanding on May 11, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

Item 1.

Name of issuer:

(a) Allogene Therapeutics, Inc.

Address of issuer's principal executive offices:

(b) 210 East Grand Avenue, South San Francisco, CA, 94080.

Item 2.

Name of person filing:

(a) The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLS P, L.P. FHMLS P, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron")

Address or principal business office or, if none, residence:

(b) The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304

Citizenship:

(c) The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G/A is incorporated by reference.

Title of class of securities:

(d) Common Stock, \$0.001 par value per share

CUSIP No.:

(e)

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

- (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (j) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 19,445,046 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS X directly holds 306,906 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X. FLS XI directly holds 753,251 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 1,941,465 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13G/A shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G/A or a member of a "group" with any other person.

Percent of class:

- (b) The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

- Not Applicable
- Item 8. Identification and Classification of Members of the Group.
Not Applicable
- Item 9. Notice of Dissolution of Group.
Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature: /s/ Jennifer Martin
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP
Name/Title: of FHMLSP, L.P., GP of Frazier Life Sciences
Public Fund, L.P.
Date: 08/14/2026

FHMLSP, L.P.

Signature: /s/ Jennifer Martin
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP
Name/Title: of FHMLSP, L.P.
Date: 08/14/2026

FHMLSP, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date: 08/14/2026

Frazier Life Sciences X, L.P.

Signature: /s/ Jennifer Martin
By Jennifer Martin, CFO of FHMLS X, L.L.C.,
Name/Title: GP of FHMLS X, L.P., GP of Frazier Life
Sciences X, L.P.
Date: 08/14/2026

FHMLS X, L.P.

Signature: /s/ Jennifer Martin
By Jennifer Martin, CFO of FHMLS X, L.L.C.,
Name/Title: GP of FHMLS X, L.P.
Date: 08/14/2026

FHMLS X, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date: 08/14/2026

Frazier Life Sciences XI, L.P.

Signature: /s/ Jennifer Martin
By Jennifer Martin, CFO of FHMLS XI, L.L.C.,
Name/Title: GP of FHMLS XI, L.P., GP of Frazier Life
Sciences XI, L.P.
Date: 08/14/2026

FHMLS XI, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C.,
GP of FHMLS XI, L.P.
Date: 08/14/2026

FHMLS XI, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date: 08/14/2026

Frazier Life Sciences XII, L.P.

Signature: /s/ Jennifer Martin
By Jennifer Martin, CFO of FHMLS XII, L.L.C.,
Name/Title: GP of FHMLS XII, L.P., GP of Frazier Life
Sciences XII, L.P.
Date: 08/14/2026

FHMLS XII, L.P.

Signature: /s/ Jennifer Martin
By Jennifer Martin, CFO of FHMLS XII, L.L.C.,
Name/Title: GP of FHMLS XII, L.P.
Date: 08/14/2026

FHMLS XII, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date: 08/14/2026

James N. Topper

Signature: /s/ Jennifer Martin
By Jennifer Martin, Attorney-in-Fact for James N.
Name/Title: Topper, pursuant to a Power of Attorney, a copy
of which was filed with the SEC on January 27,
2026
Date: 08/14/2026

Patrick J. Heron

Signature: /s/ Jennifer Martin
By Jennifer Martin, Attorney-in-Fact for Patrick
Name/Title: Heron, pursuant to a Power of Attorney, a copy of
which was filed with the SEC on January 27,
2026
Date: 08/14/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G filed on April 23, 2026)